TY - JOUR
AU - Langenberg, Karin P S
AU - Meister, Michael T
AU - Bakhuizen, Jette J
AU - Boer, Judith M
AU - van Eijkelenburg, Natasha K A
AU - Hulleman, Esther
AU - Ilan, Uri
AU - Looze, Eleonora J
AU - Dierselhuis, Miranda P
AU - van der Lugt, Jasper
AU - Breunis, Willemijn
AU - Schild, Linda G
AU - Ober, Kimberley
AU - van Hooff, Sander R
AU - Scheijde-Vermeulen, Marijn A
AU - Hiemcke-Jiwa, Laura S
AU - Flucke, Uta E
AU - Kranendonk, Mariette E G
AU - Wesseling, Pieter
AU - Sonneveld, Edwin
AU - Punt, Simone
AU - Boltjes, Arjan
AU - van Dijk, Freerk
AU - Verwiel, Eugene T P
AU - Volckmann, Richard
AU - Hehir-Kwa, Jayne Y
AU - Kester, Lennart A
AU - Koudijs, Marco M J
AU - Waanders, Esme
AU - Holstege, Frank C P
AU - Vormoor, H Josef
AU - Hoving, Eelco W
AU - van Noesel, Max M
AU - Pieters, Rob
AU - Kool, Marcel
AU - Stumpf, Miriam
AU - Blattner-Johnson, Mirjam
AU - Balasubramanian, Gnana P
AU - Van Tilburg, Cornelis M
AU - Jones, Barbara C
AU - Jones, David T W
AU - Witt, Olaf
AU - Pfister, Stefan M
AU - Jongmans, Marjolijn C J
AU - Kuiper, Roland P
AU - de Krijger, Ronald R
AU - Wijnen, Marc H W
AU - den Boer, Monique L
AU - Zwaan, C Michel
AU - Kemmeren, Patrick
AU - Koster, Jan
AU - Tops, Bastiaan B J
AU - Goemans, Bianca F
AU - Molenaar, Jan J
TI - Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program 'iTHER'.
JO - European journal of cancer
VL - 175
SN - 0014-2964
CY - Amsterdam [u.a.]
PB - Elsevier
M1 - DKFZ-2022-02304
SP - 311 - 325
PY - 2022
AB - iTHER is a Dutch prospective national precision oncology program aiming to define tumour molecular profiles in children and adolescents with primary very high-risk, relapsed, or refractory paediatric tumours. Between April 2017 and April 2021, 302 samples from 253 patients were included. Comprehensive molecular profiling including low-coverage whole genome sequencing (lcWGS), whole exome sequencing (WES), RNA sequencing (RNA-seq), Affymetrix, and/or 850k methylation profiling was successfully performed for 226 samples with at least 20
KW - Adolescent (Other)
KW - Cancer (Other)
KW - Child (Other)
KW - Hereditary (Other)
KW - Molecular biology (Other)
KW - Molecular targeted therapy (Other)
KW - Next-generation sequencing (Other)
KW - Precision medicine (Other)
LB - PUB:(DE-HGF)16
C6 - pmid:36182817
DO - DOI:10.1016/j.ejca.2022.09.001
UR - https://inrepo02.dkfz.de/record/181934
ER -